Amicus Therapeutics FOLD Stock
Amicus Therapeutics Price Chart
Amicus Therapeutics FOLD Financial and Trading Overview
| Amicus Therapeutics stock price | 14.49 USD |
| Previous Close | 0 USD |
| Open | 14.49 USD |
| Bid | 14.48 USD x 2200 |
| Ask | 14.5 USD x 2900 |
| Day's Range | 14.49 - 14.5 USD |
| 52 Week Range | 5.51 - 14.5 USD |
| Volume | 5.29M USD |
| Avg. Volume | 3.92M USD |
| Market Cap | 4.55B USD |
| Beta (5Y Monthly) | 0.481 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.09 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.5 USD |
FOLD Valuation Measures
| Enterprise Value | 4.7B USD |
| Trailing P/E | N/A |
| Forward P/E | 15.09375 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.174075 |
| Price/Book (mrq) | 16.42857 |
| Enterprise Value/Revenue | 7.409 |
| Enterprise Value/EBITDA | 112.004 |
Trading Information
Amicus Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.481 |
| 52-Week Change | 121.89% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 14.5 USD |
| 52 Week Low | 5.51 USD |
| 50-Day Moving Average | 14.4 USD |
| 200-Day Moving Average | 10.88 USD |
FOLD Share Statistics
| Avg. Volume (3 month) | 3.92M USD |
| Avg. Daily Volume (10-Days) | 2.89M USD |
| Shares Outstanding | 314M |
| Float | 311.44M |
| Short Ratio | 6.36 |
| % Held by Insiders | 0.68% |
| % Held by Institutions | 104.38% |
| Shares Short | 21.92M |
| Short % of Float | 7.03% |
| Short % of Shares Outstanding | 6.98% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | NaN |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -4.27% |
| Operating Margin (ttm) | 8.60% |
| Gross Margin | 88.50% |
| EBITDA Margin | 6.61% |
Management Effectiveness
| Return on Assets (ttm) | 2.48% |
| Return on Equity (ttm) | -11.57% |
Income Statement
| Revenue (ttm) | 634.21M USD |
| Revenue Per Share (ttm) | 2.06 USD |
| Quarterly Revenue Growth (yoy) | 23.69% |
| Gross Profit (ttm) | 561.28M USD |
| EBITDA | 41.95M USD |
| Net Income Avi to Common (ttm) | -27110000 USD |
| Diluted EPS (ttm) | -0.09 |
| Quarterly Earnings Growth (yoy) | -88.50% |
Balance Sheet
| Total Cash (mrq) | 293.54M USD |
| Total Cash Per Share (mrq) | 0.94 USD |
| Total Debt (mrq) | 442.36M USD |
| Total Debt/Equity (mrq) | 161.3 USD |
| Current Ratio (mrq) | 2.843 |
| Book Value Per Share (mrq) | 0.882 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 33.15M USD |
| Levered Free Cash Flow (ttm) | 47.84M USD |
Profile of Amicus Therapeutics
| Country | United States |
| State | NJ |
| City | Princeton |
| Address | 47 Hulfish Street |
| ZIP | 08542 |
| Phone | 609 662 2000 |
| Website | https://amicusrx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 511 |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.
Q&A For Amicus Therapeutics Stock
What is a current FOLD stock price?
Amicus Therapeutics FOLD stock price today per share is 14.49 USD.
How to purchase Amicus Therapeutics stock?
You can buy FOLD shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Amicus Therapeutics?
The stock symbol or ticker of Amicus Therapeutics is FOLD.
Which industry does the Amicus Therapeutics company belong to?
The Amicus Therapeutics industry is Biotechnology.
How many shares does Amicus Therapeutics have in circulation?
The max supply of Amicus Therapeutics shares is 314M.
What is Amicus Therapeutics Price to Earnings Ratio (PE Ratio)?
Amicus Therapeutics PE Ratio is now.
What was Amicus Therapeutics earnings per share over the trailing 12 months (TTM)?
Amicus Therapeutics EPS is -0.09 USD over the trailing 12 months.
Which sector does the Amicus Therapeutics company belong to?
The Amicus Therapeutics sector is Healthcare.
Amicus Therapeutics FOLD included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Biotechnology Total Retu XNBI | 6334.93 USD — |
+1.87
|
— — | 6201.97 USD — | 6337.77 USD — | — - | — — |
| US Tech US 700 Small Cap Index NQUS700SC | 2992.49 USD — |
-1.38
|
— — | 2986.86 USD — | 3018.97 USD — | — - | — — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 33104.2 USD — |
-0.89
|
— — | 32999.64 USD — | 33445.55 USD — | — - | — — |
| US Tech US Smart Pharmaceuticals NQSSPH | 1832.72 USD — |
+1.64
|
— — | 1800.06 USD — | 1835.39 USD — | — - | — — |
| US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG | 4054.02 USD — |
-0.25
|
— — | 4019.75 USD — | 4077 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}